Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pirtobrutinib

First Posted Date: 2024-02-14

Last Posted Date: 2024-02-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 28

Registration Number: NCT06258174

Locations: 🇺🇸
Labcorp Drug Development, Dallas, Texas, United States

A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: Lebrikizumab
Drug: Placebo

First Posted Date: 2024-02-06

Last Posted Date: 2024-06-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT06243198

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Ovarian Cancer
Recurrent Solid Tumor
Urinary Bladder Neoplasm
Esophageal Cancer
Renal Pelvis Cancer
Advanced Solid Tumor
Prostate Cancer
Metastatic Solid Tumor
Triple Negative Breast Cancer
Bladder Cancer

Interventions: Drug: LY4101174

First Posted Date: 2024-02-02

Last Posted Date: 2024-11-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 280

Registration Number: NCT06238479

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Advent Health Orlando, Orlando, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 13 locations

A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: LY3537982

First Posted Date: 2024-02-01

Last Posted Date: 2024-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT06235983

Locations: 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Phase 2

Recruiting

Conditions: Obesity
Overweight and Obesity

Interventions: Drug: LY3841136
Drug: Placebo

First Posted Date: 2024-01-30

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 250

Registration Number: NCT06230523

Locations: 🇦🇷
Centro Médico Viamonte, Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷
Centro de Investigaciones Metabólicas (CINME), Ciudad Autónoma de Buenos Aires, Argentina

and more 43 locations

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Phase 2

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: LY3541860
Drug: Placebo

First Posted Date: 2024-01-24

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 200

Registration Number: NCT06220669

Locations: 🇺🇸
Consultants in Neurology, Northbrook, Illinois, United States
🇮🇹
Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy
🇵🇱
Centrum Medyczne PRO Femina, Czeladz, Slaskie, Poland

and more 47 locations

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Pirtobrutinib
Drug: Moxifloxacin

First Posted Date: 2024-01-22

Last Posted Date: 2024-01-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 31

Registration Number: NCT06215521

Locations: 🇺🇸
Covance Clinical Research Unit 1341 Mockingbird Lane, Dallas, Texas, United States
🇺🇸
Covance Clinical Research Unit 3402 Kinsman Blvd, Madison, Wisconsin, United States

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Caffeine Tablet
Drug: Omeprazole capsule
Drug: Warfarin tablet
Drug: LOXO-305

First Posted Date: 2024-01-22

Last Posted Date: 2024-01-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT06215430

Locations: 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pirtobrutinib
Drug: Digoxin

First Posted Date: 2024-01-08

Last Posted Date: 2024-01-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT06194214

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Male

Interventions: Drug: LY3549492
Drug: [14C]-LY3549492

First Posted Date: 2024-01-08

Last Posted Date: 2024-03-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT06194500

Locations: 🇬🇧
Fortrea Clinical Research Unit, Holbeck, Leeds, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy